American Journal of Epidemiology Vol. 141, No. 6: 539-545
Copyright © 1995 by The Johns Hopkins University School of Hygiene and Public Health
research-article |
Nonsteroidal Anti-inflammatory Drugs and the Incidence of Hospitalizations for Peptic Ulcer Disease in Elderly Persons
1Department of Medicine, Division of Gastroenterology, Vanderbilt University Nashville, TN
2Department of Preventive Medicine, Vanderbilt University Nashville, TN
3Department of Medicine, Division of General Internal Medicine, Vanderbilt University Nashville, TN
Reprint requests to Dr. Walter E. Smalley, MCN-A-1128 VUMC, Nashville, TN 37208
To determine the incidence rate of serious ulcer disease among users and nonusers of nonsteroidal anti-inflammatory drugs (NSAIDs), a retrospective cohort study was done on 103,954 elderly Tennessee Medicaid recipients with 209,068 person-years of follow-up from 1984 to 1986. There were 1,371 patients hospitalized with peptic ulcer disease or upper gastrointestinal hemorrhage identified by Medicaid hospital claims and verified by review of the medical record. Ulcer hospitalization rates by NSAID exposure category, duration of use, and daily dose were determined. The rates of ulcer hospitalization among nonusers and current users of NSAIDs were 4.2 and 16.7 per 1,000 person-years, respectively, an excess rate among current users of 12.5 (95% confidence interval (Cl) 11.4–13.6) per 1,000 person-years. Among new users, the ulcer hospitalization rates were 26.3 per 1000 person-years during the first 30 days of use and 20.9 per 1,000 person-years over the next 31–180 days, representing excess ulcer hospitalization rates of 22.1 (95% Cl 18.6–25.6) and 16.7 (95% Cl 13.1–20.1) per 1,000 person-years, respectively. For long-term users (180 days or more of continuous NSAID use), the ulcer hospitalization rate remained elevated at 15.3, an excess of 12.0 (95% Cl 10.3–13.6) hospitalizations per 1,000 person-years. The excess hospitalization rates per 1,000 person-years increased with increasing dose from 6.0 (95% Cl 4.0–8.0) for the lowest dose category to 17.8 (95% Cl 15.5–20.1) for the highest. The excess rate of ulcer hospitalization for elderly NSAID users is high. These drugs should be used with caution in elderly persons, and alternatives to NSAID therapy should be strongly considered. Am J Epidemiol 1995;141:539–45.
anti-inflammatory agents, non-steroldal; cohort studies; gastrointestinal hemorrhage; Medicaid; peptic ulcer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Reichenbach, R. Sterchi, M. Scherer, S. Trelle, E. Burgi, U. Burgi, P. A. Dieppe, and P. Juni Meta-analysis: Chondroitin for Osteoarthritis of the Knee or Hip Ann Intern Med, April 17, 2007; 146(8): 580 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Namba, T. Hoshino, K.-i. Tanaka, S. Tsutsumi, T. Ishihara, S. Mima, K. Suzuki, S. Ogawa, and T. Mizushima Up-Regulation of 150-kDa Oxygen-Regulated Protein by Celecoxib in Human Gastric Carcinoma Cells Mol. Pharmacol., March 1, 2007; 71(3): 860 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Aburaya, K.-I. Tanaka, T. Hoshino, S. Tsutsumi, K. Suzuki, M. Makise, R. Akagi, and T. Mizushima Heme Oxygenase-1 Protects Gastric Mucosal Cells against Non-steroidal Anti-inflammatory Drugs J. Biol. Chem., November 3, 2006; 281(44): 33422 - 33432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Boulanger, O. Hauch, M. Friedman, T. Foster, D. Dixon, G. Wygant, and J. Menzin Warfarin Exposure and the Risk of Thromboembolic and Major Bleeding Events Among Medicaid Patients with Atrial Fibrillation Ann. Pharmacother., June 1, 2006; 40(6): 1024 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ushijima, K.-I. Tanaka, M. Takeda, T. Katsu, S. Mima, and T. Mizushima Geranylgeranylacetone Protects Membranes against Nonsteroidal Anti-Inflammatory Drugs Mol. Pharmacol., October 1, 2005; 68(4): 1156 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Tanaka, W. Tomisato, T. Hoshino, T. Ishihara, T. Namba, M. Aburaya, T. Katsu, K. Suzuki, S. Tsutsumi, and T. Mizushima Involvement of Intracellular Ca2+ Levels in Nonsteroidal Anti-inflammatory Drug-induced Apoptosis J. Biol. Chem., September 2, 2005; 280(35): 31059 - 31067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mima, S. Tsutsumi, H. Ushijima, M. Takeda, I. Fukuda, K. Yokomizo, K. Suzuki, K. Sano, T. Nakanishi, W. Tomisato, et al. Induction of Claudin-4 by Nonsteroidal Anti-inflammatory Drugs and Its Contribution to Their Chemopreventive Effect Cancer Res., March 1, 2005; 65(5): 1868 - 1876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lindblad, J. Lagergren, and L. A. Garcia Rodriguez Nonsteroidal Anti-inflammatory Drugs and Risk of Esophageal and Gastric Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 444 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Richy, O Bruyere, O Ethgen, V Rabenda, G Bouvenot, M Audran, G Herrero-Beaumont, A Moore, R Eliakim, M Haim, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach Ann Rheum Dis, July 1, 2004; 63(7): 759 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Garcia Rodriguez and S. Hernandez-Diaz Risk of Uncomplicated Peptic Ulcer among Users of Aspirin and Nonaspirin Nonsteroidal Antiinflammatory Drugs Am. J. Epidemiol., January 1, 2004; 159(1): 23 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Ray Evaluating Medication Effects Outside of Clinical Trials: New-User Designs Am. J. Epidemiol., November 1, 2003; 158(9): 915 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Russo, A. Capone, E. Attanasio, G. Baio, M. Di Martino, L. Degli Esposti, F. Marchetta, S. Buda, E. Degli Esposti, and L. Caprino Pharmacoutilization and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice Rheumatology, July 1, 2003; 42(7): 879 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J Hawkey and M J S Langman Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors Gut, April 1, 2003; 52(4): 600 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. El-Serag, D. Y. Graham, P. Richardson, and J. M. Inadomi Prevention of Complicated Ulcer Disease Among Chronic Users of Nonsteroidal Anti-inflammatory Drugs: The Use of a Nomogram in Cost-effectiveness Analysis Arch Intern Med, October 14, 2002; 162(18): 2105 - 2110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C J Hawkey, J Naesdal, I Wilson, G Langstrom, A J Swannell, R A Peacock, and N D Yeomans Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs Gut, September 1, 2002; 51(3): 336 - 343. [Abstract] [Full Text]
|
|
|
|
|
|
C J Hawkey, I Wilson, J Naesdal, G Langstrom, A J Swannell, and N D Yeomans Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users Gut, September 1, 2002; 51(3): 344 - 350. [Abstract] [Full Text]
|
|
|
|
|
|
J. G. Donahue, K. A. Chan, S. E. Andrade, A. Beck, M. Boles, D. S. M. Buist, V. J. Carey, J. M. Chandler, G. A. Chase, B. Ettinger, et al. Gastric and Duodenal Safety of Daily Alendronate Arch Intern Med, April 22, 2002; 162(8): 936 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. E. Silverstein, G. Faich, J. L. Goldstein, L. S. Simon, T. Pincus, A. Whelton, R. Makuch, G. Eisen, N. M. Agrawal, W. F. Stenson, et al. Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial JAMA, September 13, 2000; 284(10): 1247 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hernandez-Diaz and L. A. G. Rodriguez Association Between Nonsteroidal Anti-inflammatory Drugs and Upper Gastrointestinal Tract Bleeding/Perforation: An Overview of Epidemiologic Studies Published in the 1990s Arch Intern Med, July 24, 2000; 160(14): 2093 - 2099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. McAlindon, M. P. LaValley, J. P. Gulin, and D. T. Felson Glucosamine and Chondroitin for Treatment of Osteoarthritis: A Systematic Quality Assessment and Meta-analysis JAMA, March 15, 2000; 283(11): 1469 - 1475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Bauer, D. Black, K. Ensrud, D. Thompson, M. Hochberg, M. Nevitt, T. Musliner, D. Freedholm, and for the Fracture Intervention Trial Research Group Upper Gastrointestinal Tract Safety Profile of Alendronate: The Fracture Intervention Trial Arch Intern Med, February 28, 2000; 160(4): 517 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Smalley, W. A. Ray, J. Daugherty, and M. R. Griffin Use of Nonsteroidal Anti-inflammatory Drugs and Incidence of Colorectal Cancer: A Population-Based Study Arch Intern Med, January 25, 1999; 159(2): 161 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Kokoska, G. S. Smith, Y. Deshpande, A. B. Wolff, and T. A. Miller Indomethacin increases susceptibility to injury in human gastric cells independent of PG synthesis inhibition Am J Physiol Gastrointest Liver Physiol, October 1, 1998; 275(4): G620 - G628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Smalley, M. R. Griffin, R. L. Fought, L. Sullivan, and W. A. Ray Effect of a Prior-Authorization Requirement on the Use of Nonsteroidal Antiinflammatory Drugs by Medicaid Patients N. Engl. J. Med., June 15, 1995; 332(24): 1612 - 1617. [Abstract] [Full Text] [PDF]
|
|